NON-LINEAR PHARMACOKINETICS FOR THE ELIMINATION OF 5-FLUOROURACIL AFTER INTRAVENOUS ADMINISTRATION IN CANCER-PATIENTS

被引：50

作者：

MCDERMOTT, BJ ^{[1
]}

VANDENBERG, HW ^{[1
]}

MURPHY, RF ^{[1
]}

机构：

[1] QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1982年 / 9卷 / 03期

关键词：

D O I：

10.1007/BF00257748

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：173 / 178

页数：6

相关论文

共 29 条

[1] AMBRE JJ, 1971, J LAB CLIN MED, V78, P343
[2] CALVERT AH, 1980, CANCER TOPICS, V3, P2
[3] CANO JP, 1979, B CANCER, V66, P67
[4] CHADWICK M, 1972, CANCER RES, V32, P1045
[5] FLUOROURACIL THERAPY IN PATIENTS WITH CARCINOMA OF LARGE BOWEL - PHARMACOKINETIC COMPARISON OF VARIOUS RATES AND ROUTES OF ADMINISTRATION
CHRISTOPHIDIS, N
VAJDA, FJE
LUCAS, I
DRUMMER, O
MOON, WJ
LOUIS, WJ
[J]. CLINICAL PHARMACOKINETICS, 1978, 3 (04) : 330 - 336
[6] NON-LINEAR PHARMACOKINETIC MODELS FOR 5-FLUOROURACIL IN MAN - INTRAVENOUS AND INTRAPERITONEAL ROUTES
COLLINS, JM
DEDRICK, RL
KING, FG
SPEYER, JL
MYERS, CE
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (02) : 235 - 246
[7] CURRY SH, 1977, DRUG DISPOSITION PHA, P155
[8] EDELSTYN GA, 1975, LANCET, V2, P209
[9] EDELSTYN GA, 1977, LANCET, V1, P592
[10] EDELSTYN GA, 1977, LANCET, V2, P396